Reaction
Herpes Ophthalmic reporting signals
As of the last recalculation, Herpes Ophthalmic appears in 1,289 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is PREDNISOLONE ACETATE (PRR 20.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Prednisolone Acetate | 13 | 20.5 | 20.5 |
| Valacyclovir Hydrochloride | 70 | 16.9 | 16.9 |
| Ganciclovir | 10 | 15.9 | 15.9 |
| Valacyclovir | 38 | 15.1 | 15.1 |
| Brimonidine Tartrate | 13 | 11.9 | 11.9 |
| Brinzolamide | 6 | 11.2 | 11.2 |
| Acyclovir | 64 | 9.5 | 9.5 |
| Cenegermin-Bkbj | 7 | 9.4 | 9.4 |
| Ocrelizumab | 35 | 9.3 | 9.3 |
| Busulfan | 9 | 9.3 | 9.3 |
| Carboxymethylcellulose Sodium | 5 | 8.6 | 8.6 |
| Timolol | 6 | 8.1 | 8.1 |
| Faricimab | 4 | 8.0 | 8.0 |
| Upadacitinib | 38 | 7.7 | 7.7 |
| Bimatoprost | 12 | 6.8 | 6.8 |
| Lifitegrast | 6 | 6.0 | 6.0 |
| Polatuzumab Vedotin | 3 | 5.0 | 5.0 |
| Peginterferon Beta-1A | 4 | 4.9 | 4.9 |
| Aflibercept | 9 | 4.7 | 4.7 |
| Dupilumab | 100 | 3.5 | 3.5 |
| Natalizumab | 39 | 3.5 | 3.5 |
| Bimekizumab | 4 | 3.0 | 3.0 |